Elsevier

Clinical Therapeutics

Volume 28, Issue 8, August 2006, Pages 1079-1106
Clinical Therapeutics

Tigecycline: A glycylcycline antimicrobial agent

https://doi.org/10.1016/j.clinthera.2006.08.011Get rights and content

Abstract

Background:

Tigecycline, the first glycylcycline to be approved by the US Food and Drug Administration, is a structural analogue of minocycline that was designed to avoid tetracycline resistance mediated by ribosomal protection and drug efflux. It is indicated for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections and is available for intravenous administration only.

Objective:

This article summarizes the in vitro and in vivo activities and pharmacologic and pharmacokinetic properties of tigecycline, and reviews its clinical efficacy and tolerability profile.

Methods:

Relevant information was identified through a search of MEDLINE (1966-April 2006), Iowa Drug Information Service (1966-April 2006), and International Pharmaceutical Abstracts (1970-April 2006) using the terms tigecycline, GAR-936, and glycylcycline. Also consulted were abstracts and posters from meetings of the Infectious Diseases Society of America and the Interscience Conference on Antimicrobial Agents and Chemotherapy (1999–2006) and documents provided for formulary consideration by the US manufacturer of tigecycline.

Results:

Like the tetracyclines, tigecycline binds to the 30S subunit of bacterial ribosomes and inhibits protein synthesis by preventing the incorporation of amino acid residues into elongating peptide chains. In vitro, tigecycline exhibits activity against a wide range of clinically significant gram-positive and gram-negative bacteria, including multidrug-resistant strains (eg, oxacillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum β-lactamase-producing Enterobacteriaceae), and anaerobes (eg, Bacteroides spp). In pharmacokinetic studies in human adults, tigecycline had a large Vd (7–9 L/kg), was moderately bound to plasma protein (71%–89%), had an elimination t1/2 of 42.4 hours, and was eliminated primarily by biliary/fecal (59%) and renal (33%) excretion. Dose adjustment did not appear to be necessary based on age, sex, renal function, or mild to moderate hepatic impairment (Child-Pugh class A–B). In patients with severe hepatic impairment (Child-Pugh class C), the maintenance dose should be reduced by 50%. In 4 Phase III clinical trials in patients with complicated skin and skin-structure infections and complicated intra-abdominal infections, tigecycline was reported to be noninferior to its comparators (vancomycin + aztreonam in 2 studies and imipenem/cilastatin in 2 studies), with clinical cure rates among clinically evaluable patients of >80% (P < 0.001 for noninferiority). The most frequently reported (≥5 %) adverse events with tigecycline were nausea (28.5%), vomiting (19.4%), diarrhea (11.6%), local IV-site reaction (8.2%), infection (6.7%), fever (6.3%), abdominal pain (6.0%), and headache (5.6%). The recommended dosage of tigecycline is 100 mg IV given as a loading dose, followed by 50 mg IV g12h for 5 to 14 days.

Conclusions:

In clinical trials, tigecycline was effective for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections. With the exception of gastrointestinal adverse events, tigecycline was generally well tolerated. With a broad spectrum of activity that includes multidrug-resistant gram-positive and gram-negative pathogens, tigecycline may be useful in the treatment of conditions caused by these pathogens.

References (101)

  • FritscheT.R. et al.

    Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and noso comial pneumonia

    Diagn Microbiol Infect Dis

    (2005)
  • GalesA.C. et al.

    Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates

    Diagn Microbiol Infect Dis

    (2000)
  • FritscheT.R. et al.

    Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates

    Diagn Microbiol Infect Dis

    (2005)
  • FritscheT.R. et al.

    Antimicrobial activity of tigecycline (GAR936) tested against 3498 recent iso lates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

    Int J Antimicrob Agents

    (2004)
  • DeshpandeL.M. et al.

    GAR-936 (9-t-butylglycylamidominocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria

    Int J Antimicrob Agents

    (2001)
  • RoblinP.M. et al.

    In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

    Int J Antimicrob Agents

    (2000)
  • PostierR.G. et al.

    Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

    Clin Ther

    (2004)
  • ConteJ.E. et al.

    Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

    Int J Antimicrob Agents

    (2005)
  • PatelR. et al.

    In vitro activity of GAR-936 against vancomycin-resistant entero cocci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

    Diagn Microbiol Infect Dis

    (2000)
  • MeagherA.K. et al.

    Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent

    Diagn Microbiol Infect Dis.

    (2005)
  • SacchidanandS. et al.

    Efficacy and safety of tigecy cline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

    Int J Infect Dis

    (2005)
  • NathwaniD.

    Tigecycline: Clinical evidence and formulary positioning

    Int J Antimicrob Agents

    (2005)
  • DiekemaD.J. et al.

    Antimicrobial resistance trends and outbreak frequency in United States hospitals

    Clin Infect Dis

    (2004)
  • HiramatsuK. et al.

    Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility

    J Antimicrob Chemother

    (1997)
  • Centers for Disease Control and Prevention (CDC)

    Staphylococcus aureus resistant to vancomycin—United States, 2002

    MMWR Morb Mortal Wkly Rep

    (2002)
  • MillerD. et al.

    Public health dispatch: Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002

    MMWR Morb Mortal Wkly Rep

    (2002)
  • WeberJ.T.

    Community-associated methicillin-resistant Staphylococcus aureus

    Clin Infect Dis

    (2005)
  • BratuS. et al.

    Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection

    Antimicrob Agents Chemother

    (2005)
  • LolansL. et al.

    First nosocomial outbreak of Pseudomonas aeruginosa producing an integronborne metallo-beta-lactamase (VIM-2) in the United States

    Antimicrob Agents Chemother

    (2005)
  • Infectious Diseases Society of America

    Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates… A Public Health Crisis Brews

  • ScheinfeldN.

    Tigecycline: A review of a new glycylcycline antibiotic

    J Dermatolog Treat

    (2005)
  • Tygacil [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals;...
  • PankeyG.A.

    Tigecycline

    J Antimicrob Chemother.

    (2005)
  • ZhanelG.G. et al.

    The glycylcyclines: A comparative review with the tetracyclines

    Drugs

    (2004)
  • RubinsteinE. et al.

    Tigecycline: A novel glycylcyline

    Drugs

    (2005)
  • BergeronJ et al.

    Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-medicated ribosomal protection

    Antimicrob Agents Chemother

    (1996)
  • JacobusN.V. et al.

    In vitro activities of tigecycline against the Bacteroides fragilis group

    Antimicrob Agents Chemother

    (2004)
  • GoldsteinE.J. et al.

    Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

    Antimicrob Agents Chemother

    (2000)
  • BradfordP.A. et al.

    In vitro activity of tigecycline against isolates from pa tients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

    Clin Infect Dis

    (2005)
  • BouchillonS. et al.

    Methicillin-resistant Staphylococcus aureus (1030) collected from a recent global population: Tigecycline in vitro evaluation

  • JohnsonB. et al.

    Vancomycin-resistant enterococci (VRE): A global problem: Evaluation of tigecycline against recent isolates from multi-centers globally

  • LaPlanteK.L. et al.

    Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

    Diagn Microbiol Infect Dis

    (2004)
  • TenoverF.C. et al.

    Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

    Antimicrob Agents Chemother

    (2004)
  • BozdoganB. et al.

    Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

    J Antimicrob Chemother

    (2003)
  • JohnsonB. et al.

    Determining tigecycline's in vitro activity against multi-drug re sistant Enterobacteriaceae from the TEST program—global data

  • FritscheT.R. et al.

    Activity of tigecycline tested against tetracycline-resistant Enterobacteriaceae

  • BetriuC et al.

    In vitro activity of tigecycline and comparative antimicrobial agents against ampicillin-resistant Haemophilus influenzae isolates

  • Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints: Informational Supplement—Second Edition

    (2006)
  • BradfordP.A. et al.

    Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method

    Antimicrob Agents Chemother

    (2005)
  • HopeR. et al.

    Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines

    J Antimicrob Chemother

    (2005)
  • Cited by (144)

    • Tigecycline therapy in pediatric patients with multidrug resistant bacteremia

      2020, Enfermedades Infecciosas y Microbiologia Clinica
    • Systemic Antibacterial Agents

      2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
    View all citing articles on Scopus
    View full text